NSC 185058 (NSC-185058) is an inhibitor of ATG4B which is a major cysteine protease, and inhibition of ATG4B by NSC185058 markedly attenuates autophagic activity. NSC185058 acts by inhibiting autophagy and showing a negative impact on osteosarcoma tumors.
Physicochemical Properties
| Molecular Formula | C11H9N3S |
| Molecular Weight | 215.27426 |
| Exact Mass | 215.052 |
| CAS # | 39122-38-8 |
| PubChem CID | 750538 |
| Appearance | Light yellow to yellow solid powder |
| Density | 1.323g/cm3 |
| Boiling Point | 378.2ºC at 760 mmHg |
| Flash Point | 182.5ºC |
| Index of Refraction | 1.72 |
| LogP | 2.337 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 15 |
| Complexity | 220 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | UGWOJXZJIZUKDP-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C11H9N3S/c15-11(9-5-1-3-7-12-9)14-10-6-2-4-8-13-10/h1-8H,(H,13,14,15) |
| Chemical Name | N-Pyridin-2-ylpyridine-2-carbothioamide |
| Synonyms | NSC185058; NSC-185058; NSC 185058; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo | An antagonist of ATG4B is NSC185058. By reversibly altering ATG8 to encourage autophagosomes, ATG4B promotes autophagy. Radiation therapy (RT) has an enhanced antitumor activity when it contains ATG4B-conjugated NSC185058. NSC185058 was found to decrease the tumorigenicity of astroblastoma (GBM) cells and increase the antitumor activity of RT in an orthotopic GBM xenograft model [1]. |
| References |
[1]. MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. Cancer Cell. 2017 Dec 11;32(6):840-855.e8. |
Solubility Data
| Solubility (In Vitro) | DMSO : ≥ 125 mg/mL (~580.67 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (9.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6453 mL | 23.2266 mL | 46.4533 mL | |
| 5 mM | 0.9291 mL | 4.6453 mL | 9.2907 mL | |
| 10 mM | 0.4645 mL | 2.3227 mL | 4.6453 mL |